Nathalie Asherie

7PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

Ariela Arad, Maya Katz, Eyal Lebel

|Dec 09, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld

|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel

|Feb 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Nico Gagelmann, Danai Dima, Maximilian Merz

|Jul 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Vladimir Vainstein, Batia Avni, Sigal Grisariu

|Apr 18, 2023
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.

T Dubnikov Sharon, M Assayag, B Avni

Pageof 2

Frequent Collaborators

6 joint publications

Moshe E Gatt

4 joint publications

Batia Avni

4 joint publications

Polina Stepensky

4 joint publications

Eyal Lebel